Certara (CERT) Stock Price, News & Analysis

Company Overview

Certara, Inc. (NASDAQ:CERT) provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.

Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis. Certara also provides consulting and scientific services, including regulatory strategy, model-informed drug development, biostatistics, pharmacovigilance, and medical and regulatory writing.

Certara serves pharmaceutical and biotechnology companies, academic and research institutions, and regulatory agencies internationally. The company was founded in 2008 through the combination of consulting and technology businesses focused on drug development and became a publicly traded company on the Nasdaq in 2020. Its operations and customer base span North America, Europe, and Asia-Pacific.

Key Stats

• Today's Range: $9.28 to $9.63
• 50-Day Range: $7.42 to $10.07
• 52-Week Range: $4.45 to $12.94
• Volume: 1.82 million shs
• Average Volume: 3.23 million shs
• Market Capitalization: $1.43 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.82
• Consensus Rating: Hold

Certara Stock Analysis - MarketRank™

Certara scored higher than 39% of companies evaluated by MarketBeat, and ranked 695th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Certara has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 1 strong buy rating, 4 buy ratings, 6 hold ratings, and 1 sell rating.

Downside Risk

Certara has a consensus price target of $8.82, representing about 5.8% downside from its current price of $9.36.

Amount of Analyst Coverage

Certara has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 27.27%

Earnings Growth

Earnings for Certara are expected to grow by 27.27% in the coming year, from $0.22 to $0.28 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Certara is -20.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Certara is -20.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Certara has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.36% of the float of Certara has been sold short.

Short Interest Ratio / Days to Cover

Certara has a short interest ratio ("days to cover") of 8.97.

Change versus previous month

Short interest in Certara has recently decreased by 3.85%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Certara does not currently pay a dividend.

Dividend Growth

Certara does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.97

News Sentiment

Certara has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Certara this week, compared to 4 articles on an average week.

Search Interest

7 people have searched for CERT on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Certara to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Certara insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.08% of the stock of Certara is held by insiders.

Percentage Held by Institutions

73.96% of the stock of Certara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Technology
• Sub-Industry: Healthcare Technology
• Current Symbol: NASDAQ:CERT
• CIK: 1827090
• Web: www.certara.com
• Phone: 609-716-7900
• Fax: N/A
• Employees: 1,576
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Certara: $8.82
• High Price Target: $11.00
• Low Price Target: $6.00
• Potential Upside/Downside: -5.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.42
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 42.55
• P/E Growth: N/A
• Net Income: -$1.60 million
• Net Margins: -16.75%
• Pretax Margin: -3.83%
• Return on Equity: 3.86%
• Return on Assets: 2.65%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 2.55
• Quick Ratio: 2.55

Sales & Book Value

• Annual Sales: $418.84 million
• Price / Sales: 3.41
• Cash Flow: $0.74 per share
• Price / Cash Flow: 12.69
• Book Value: $6.67 per share
• Price / Book: 1.40

Miscellaneous

• Outstanding Shares: 152,540,000
• Free Float: 150,892,000
• Market Cap: $1.43 billion
• Optionable: Optionable
• Beta: 1.42